Comment on

• Commentary on "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer." Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J, Division of Urologic Oncology, Department of Urology, University of Michigan, MI. N Engl J Med 2014; 371(11):1028-38.

  Palapattu GS. Palapattu GS. Urol Oncol. 2016 Nov;34(11):520. doi: 10.1016/j.urolonc.2015.12.011. Epub 2016 Mar 7. Urol Oncol. 2016. PMID: 26964769 No abstract available.